TARGETS

 

Master Invadopodial Regulator 1 (MIR-01)

MIR-01 is a master regulator of invadopodia and cancer invasiveness, playing a dominant role similar to oncogenic RAS in cancer formation. Antapodia Therapeutics pioneered the identification of MIR-01 as a critical component of a protein complex that initiates invadopodia formation. MIR-01 also is known to serve as a positive regulator of critical oncogenic signaling pathways, including Wnt, Notch, and FoxM1, thereby promoting tumor growth (Figure 1). In invasive cancer cells, MIR-01 predominantly localizes to the invadopodia (Figure 2). The expression of MIR-01 is deficient in normal cells while it is upregulated in cancer cells, making it an ideal and safe therapeutic target (Figure 3). Genetic knockdown of MIR-01 blocks the formation of invadopodia in invasive cancer cells (Figure 4), thereby inhibiting cancer invasiveness (Figure 5) and distant metastasis in various types of cancers (Figure 5).

Figure 1. MIR-01 regulates the invadopodia formation and critical oncogenic signaling pathways

Figure 1. MIR-1 is specifically localized to the invadopodia in invasive cancer cells

Figure 2. MIR-01 is specifically localized to the invadopodia on invasive cancer cells

Figure 1. MIR-1 is specifically localized to the invadopodia in invasive cancer cells

Figure 3. MIR-01 expression is upregulated in the cytoplasm of HCC (A) and TNBC cells (B)

Figure 2. MIR-1 expression is upregulated in cancer cells

HCC, hepatocellular carcinoma; TNBC, triple-negative breast cancer.

Figure 4. Genetic knockdown of MIR-01 abrogates the invadopodial formation in invasive cancer cells

Figure 3. Genetic knockdown of MIR-1 abrogates invadopodia formation in invasive cancer cells

Invadopodia are represented by cortactin and F-actin colocalized dots (yellow) in these confocal images.

Figure 5. Genetic knockdown of MIR-01 markedly attenuates the invasiveness of cancer cells

Figure 4. Genetic knockdown of MIR-1 abrogates cancer cell invasiveness

Figure 6. Genetic knockdown of MIR-01 abolishes cancer metastasis

Figure 5. Genetic knockdown of MIR-1 cancels cancer metastasis

TNBC, triple-negative breast cancer; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal epithelial cancer

Logo_vertical_light.png

Designed by Justin V. Tsai in 2021

Copyright © Antapodia Therapeutics, Inc., WA, USA. All Rights Reserved.

Search